Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03691909 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis
A Phase 1 study, sponsored by Hope Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03691909 is a Phase 1 study that has completed, run by Hope Biosciences. The registered enrollment target is 15 participants.
The verdict
NCT03691909, a Phase 1 study, has completed, sponsored by Hope Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Hope Biosciences is conducting a research study of an investigational product called Hope Biosciences autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment for Rheumatoid Arthritis (RA). The study purpose is to evaluate the safety profile of a single IV infusion of HB-adMSCs in subjects with clinical diagnosis of RA.
Interventions
- BIOLOGICAL HB-adMSCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2020-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03691909
The ClinicalTrials.gov registry entry for NCT03691909 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hope Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HB-adMSCs is the first listed.
NCT03691909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03691909 about?
NCT03691909 is a clinical study titled "Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis". Hope Biosciences is conducting a research study of an investigational product called Hope Biosciences autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment for Rheumatoid Arthritis (RA). The study purpose is to evaluate the safety profile of a single IV...
What is the current status of trial NCT03691909?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-09-25. Estimated completion is 2020-09-28.
What interventions are being tested in trial NCT03691909?
The interventions under investigation include: HB-adMSCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT03691909?
This trial is sponsored by Hope Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.